Mar 27, 2024 • 4:05 PM EDT Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
Mar 25, 2024 • 8:00 AM EDT Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
Mar 22, 2024 • 9:15 AM EDT Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response